Texas Pharmacy Loses License Over Risky Drug Fills
Published Date: 4/14/2025
Notice
Summary
Mariste Pharmacy in Texas lost its DEA license because it kept filling risky prescriptions without checking for abuse and broke important drug storage and record rules. They didn’t ask for a hearing to defend themselves, so the suspension and revocation stand. This means Mariste can’t legally handle controlled drugs anymore, protecting public safety starting from May 2024.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA revokes Mariste Pharmacy registration
The Drug Enforcement Administration revoked Mariste Pharmacy's DEA Certificate of Registration No. FM2279431. The final Order revoking the registration is effective May 14, 2025, which means Mariste Pharmacy no longer holds a DEA registration to distribute or dispense controlled substances.
Immediate suspension issued May 20, 2024
On May 20, 2024, the DEA issued an Order to Show Cause and Immediate Suspension of Registration for Mariste Pharmacy under 21 U.S.C. 824(d), finding the continued registration could be an imminent danger to public health or safety. That suspension preceded the final revocation.
DEA denies pending and future Texas registrations
The Order also denies any pending applications of Mariste Pharmacy to renew or modify this registration and denies any other pending application for additional registration in Texas. This denial is part of the final action effective May 14, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-06311, Eagle Pharmacy; Decision and Order
Eagle Pharmacy in Houston lost its DEA license because it filled risky prescriptions without fixing warning signs, breaking federal and Texas laws. They missed the deadline to ask for a hearing, so the decision to revoke their registration stands. This means Eagle Pharmacy can no longer legally handle controlled substances, affecting their business and customers immediately.
Next: 2025-06318, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a closed virtual meeting on May 8, 2025, to review important grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies, ensuring their ideas stay private and protected. No public attendance or money changes are involved, but this review helps decide which projects get support.